

# Explore a treatment option for NYHA Class II–III obstructive HCM

---

## Learn more at **BMS Booth 800**

The FDA has approved a treatment option for appropriate patients with symptomatic NYHA Class II–III obstructive HCM. Visit BMS Booth 800 to learn about the MOA, examine the endpoints, and read about the safety profile of this treatment option.

FDA=US Food and Drug Administration; HCM=hypertrophic cardiomyopathy; MOA=mechanism of action;  
NYHA=New York Heart Association.